SCOPUS 정보 검색 플랫폼

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 255-257

Immunotherapy: Is it different for sarcomas?

(3) Cleton Jansen, Anne Marie a Buddingh, Emilie P a Lankester, Arjan C a

a LEIDEN UNIVERSITY MEDICAL CENTER (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD163 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MIFAMURTIDE;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG RESPONSE; GENE EXPRESSION PROFILING; HUMAN; LYMPHOCYTIC INFILTRATION; MESENCHYME CELL; METASTASIS; NOTE; OSTEOSARCOMA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

EID: 84884909814 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.4161/onci.1.2.18345 Document Type: Note

Times cited : (4)

References (10)

1
- 0026060863
- The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893
- Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991; 3-11.
- (1991) Clin Orthop Relat Res , pp. 3-11
- Coley, W.B.¹

2
- 0026602628
- Coley's toxins in perspective
- Starnes CO. Coley's toxins in perspective. Nature 1992; 357:11-2; http://dx.doi.org/10.1038/357011a0
- (1992) Nature , vol.357 , pp. 11-12
- Starnes, C.O.¹

3
- 77950950894
- Macrophage diversity enhances tumor progression and metastasis
- Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; http://dx.doi.org/10.1016/j.cell.2010.03.014
- (2010) Cell , vol.141 , pp. 39-51
- Qian, B.Z.¹ Pollard, J.W.²

4
- 72249102176
- Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency
- Fischer-Valuck BW, Barrilleaux BL, Phinney DG, Russell KC, Prockop DJ, O'Connor KC. Migratory response of mesenchymal stem cells to macrophage migration inhibitory factor and its antagonist as a function of colony-forming efficiency. Biotechnol Lett 2010; 32:19-27; http://dx.doi.org/10.1007/s10529-009-0110-6
- (2010) Biotechnol Lett , vol.32 , pp. 19-27
- Fischer-Valuck, B.W.¹ Barrilleaux, B.L.² Phinney, D.G.³ Russell, K.C.⁴ Prockop, D.J.⁵ O'Connor, K.C.⁶

5
- 79954573473
- Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents
- Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage-activating agents. Clin Cancer Res 2011; 17:2110-9; http://dx.doi.org/10.1158/1078-0432.CCR-10-2047
- (2011) Clin Cancer Res , vol.17 , pp. 2110-2119
- Buddingh, E.P.¹ Kuijjer, M.L.² Duim, R.A.³ Burger, H.⁴ Agelopoulos, K.⁵ Myklebost, O.⁶

6
- 20144380941
- Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
- Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004-11; http://dx.doi.org/10.1200/JCO.2005.06.031
- (2005) J Clin Oncol , vol.23 , pp. 2004-2011
- Meyers, P.A.¹ Schwartz, C.L.² Krailo, M.³ Kleinerman, E.S.⁴ Betcher, D.⁵ Bernstein, M.L.⁶

7
- 39149136228
- Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group
- Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26:633-8; http://dx.doi.org/10.1200/JCO.2008.14.0095
- (2008) J Clin Oncol , vol.26 , pp. 633-638
- Meyers, P.A.¹ Schwartz, C.L.² Krailo, M.D.³ Healey, J.H.⁴ Bernstein, M.L.⁵ Betcher, D.⁶

8
- 23944474283
- Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series
- Müller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005; 44:475-80; http://dx.doi.org/10.1080/02841860510029978
- (2005) Acta Oncol , vol.44 , pp. 475-480
- Müller, C.R.¹ Smeland, S.² Bauer, H.C.³ Saeter, G.⁴ Strander, H.⁵

9
- 76749141740
- The role of interferons in the treatment of osteosarcoma
- Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010; 54:350-4; http://dx.doi.org/10.1002/pbc.22136
- (2010) Pediatr Blood Cancer , vol.54 , pp. 350-354
- Whelan, J.¹ Patterson, D.² Perisoglou, M.³ Bielack, S.⁴ Marina, N.⁵ Smeland, S.⁶

10
- 80052839972
- Macrophage infiltration predicts a poor prognosis for human ewing sarcoma
- Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011; 179:1157-70; http://dx.doi.org/10.1016/j.ajpath.2011.05.034
- (2011) Am J Pathol , vol.179 , pp. 1157-1170
- Fujiwara, T.¹ Fukushi, J.² Yamamoto, S.³ Matsumoto, Y.⁴ Setsu, N.⁵ Oda, Y.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.